drug
pexidartinib hydrochloride
Marketedupdated 3mo agoby Daiichi Sankyo Co Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying pexidartinib hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 21, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Jul 24, 2038formulationUS 10435404
- Jul 24, 2038formulationUS 10435404
- Jul 24, 2038formulationUS 10941142
- Jul 24, 2038formulationUS 10941142
- Jul 24, 2038method-of-use (U-2606)US 10961240
- Jul 24, 2038method-of-use (U-2606)US 10961240
- May 5, 2036method-of-use (U-2606)US 10189833
- May 5, 2036method-of-use (U-2606)US 10189833
- May 5, 2036compositionUS 10730876
- May 5, 2036compositionUS 10730876
- May 5, 2036compositionUS 9802932
- May 5, 2036compositionUS 9802932
- Jun 8, 2033method-of-use (U-2606)US 9358235
- Jun 8, 2033method-of-use (U-2606)US 9358235
- May 4, 2033compositionUS 7893075
- May 4, 2033compositionUS 7893075
- Apr 19, 2028method-of-use (U-2606)US 84611691.7y
- Apr 19, 2028method-of-use (U-2606)US 84611691.7y
- Nov 21, 2027compositionUS 84047001.3y
- Nov 21, 2027compositionUS 84047001.3y
- Nov 21, 2027compositionUS 87227021.3y
- Nov 21, 2027compositionUS 87227021.3y
- Nov 21, 2027compositionUS 91692501.3y
- Nov 21, 2027compositionUS 91692501.3y
FDA exclusivities (2)
- Aug 2, 2026ODE-250Orphan Drug (7y)
- Aug 2, 2026ODE*ODE*
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 50m ago
Found something off?
comments(0)
5-min edit window · permanent after that